GO:0005134 interleukin-2 receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005134 interleukin-2 receptor binding is a molecular function describing the binding of a ligand to an interleukin-2 receptor (IL-2R).
• The IL-2 receptor is a multi-subunit complex; high-affinity binding requires the alpha (CD25), beta (CD122), and common gamma (CD132) chains.
• IL-2R binding triggers signaling through JAK/STAT, PI3K, and Ras/MAPK pathways, driving T-cell proliferation and survival.
• Soluble CD25 (sCD25) is generated by ADAM10-mediated cleavage of IL-2R alpha and can modulate IL-2 availability.
• Engineered IL-2 mimics and IL-2R-targeted therapies are being developed for cancer and autoimmune diseases.
• CRISPR-based models (knockout, knock-in, point mutation) are essential to dissect IL-2R binding and signaling in immune cells.
Description
Interleukin-2 receptor binding (GO:0005134) is the molecular function of selectively interacting with an interleukin-2 receptor (IL-2R). This binding event is the first step in IL-2-mediated signaling, which is critical for the proliferation, survival, and effector functions of T lymphocytes and natural killer cells. The IL-2 receptor is not a single protein but a complex of up to three subunits: IL-2R alpha (CD25), IL-2R beta (CD122), and the common gamma chain (CD132). The affinity of IL-2 for its receptor varies dramatically depending on which subunits are present, with the trimeric high-affinity receptor (Kd ~10 pM) being essential for responses to low physiological concentrations of IL-2. Understanding the molecular details of this binding is fundamental for immunology research and for the development of therapeutics that either block or enhance IL-2 signaling. Researchers study GO:0005134 to elucidate how immune responses are initiated and regulated, and to design drugs that target the IL-2/IL-2R axis in cancer, autoimmunity, and transplantation. The binding event is also a paradigm for cytokine-receptor interactions, involving conformational changes and assembly of signaling-competent complexes. Recent advances in protein engineering have produced IL-2 mimics that selectively bind different IL-2R subunits, offering new avenues for immunotherapy. Moreover, the regulation of IL-2R binding by proteolytic shedding (e.g., ADAM10-mediated generation of soluble CD25) adds another layer of complexity. This article provides a comprehensive overview of the definition, mechanism, key genes, disease relevance, and research methods for GO:0005134, with a focus on CRISPR-based approaches to study this function.
interleukin-2 receptor binding At A Glance
| GO ID | GO:0005134 |
|---|---|
| GO term | interleukin-2 receptor binding |
| Ontology | molecular_function |
| Synonym | IL-2, interleukin-2 receptor ligand |
| Definition | Binding to an interleukin-2 receptor. |
| Major function | Mediates cytokine-receptor interaction to initiate IL-2 signaling. |
| Related cellular component | IL-2 receptor complex (CD25/CD122/CD132). |
| Related biological process | T cell activation, proliferation, and survival. |
| Key ligands | IL-2, IL-15, engineered mimics. |
What Is GO:0005134?
According to the Gene Ontology, GO:0005134 interleukin-2 receptor binding is defined as the binding to an interleukin-2 receptor. In other words, it is the molecular function of a ligand (such as interleukin-2 or an engineered mimic) physically interacting with the IL-2 receptor complex on the cell surface. This binding is non-covalent and highly specific, and it can occur with different affinities depending on the receptor subunits involved. The term is used to annotate gene products that exhibit this binding activity, including cytokines, synthetic proteins, and antibodies that target the receptor.
Why Is interleukin-2 receptor binding Important in Cell Biology?
Interleukin-2 receptor binding is a central event in immune regulation, as it controls the magnitude and duration of T-cell responses. Dysregulation of this binding is implicated in autoimmune diseases, transplant rejection, and cancer. Therapeutically, blocking IL-2R binding with antibodies (e.g., basiliximab) prevents organ rejection, while enhancing binding with IL-2 agonists boosts anti-tumor immunity. Furthermore, the design of IL-2 mimics with selective receptor binding profiles is a promising strategy to reduce toxicity and improve efficacy. Thus, understanding GO:0005134 is essential for both basic immunology and translational medicine.
• Controls T-cell proliferation and survival via JAK/STAT, PI3K, and MAPK pathways.
• Determines the affinity and specificity of IL-2 signaling through different receptor subunit combinations.
• Soluble CD25 generated by ADAM10 cleavage modulates IL-2 bioavailability and immune responses.
• Targeted by immunosuppressive drugs (e.g., triptolide) that interfere with IL-2/IL-2R signaling.
• Engineered IL-2 mimics with altered receptor binding are in clinical development for cancer immunotherapy.
• IL-2R alpha (CD25) is a marker of regulatory T cells and a target for depleting antibodies.
• Mutations affecting IL-2R subunits cause severe immunodeficiency (e.g., CD25 deficiency).
• IL-2 receptor binding is a model for studying cytokine-receptor assembly and allostery.
• Biosensor and structural studies of IL-2R binding inform drug design.
• CRISPR screens can identify regulators of IL-2R binding and signaling.
Molecular Mechanism of interleukin-2 receptor binding
Ligand recognition and receptor assembly
In simple terms: IL-2 binds to the IL-2 receptor subunits in a stepwise manner, forming a complex that can send signals into the cell.
Interleukin-2 (IL-2) first binds to the IL-2R alpha chain (CD25) with low affinity, which then recruits the beta (CD122) and common gamma (CD132) chains to form a high-affinity signaling complex. This assembly is essential for transmitting signals at physiological IL-2 concentrations. The binding interface involves conserved residues on IL-2 that interact with distinct domains on each receptor subunit.
Conformational changes and signal initiation
In simple terms: When IL-2 binds, the receptor changes shape, allowing enzymes inside the cell to become active and start signaling.
Binding of IL-2 induces conformational changes in the receptor complex that bring the intracellular domains of the beta and gamma chains into proximity, allowing associated Janus kinases (JAK1 and JAK3) to phosphorylate each other and downstream targets. This initiates signaling cascades including JAK/STAT, PI3K/Akt, and Ras/MAPK, which drive gene expression programs for T-cell proliferation and survival.
Affinity modulation by receptor subunits
In simple terms: Different combinations of receptor subunits bind IL-2 with different strengths, which affects how sensitive a cell is to IL-2.
The IL-2 receptor exists in three forms: low-affinity (alpha alone), intermediate-affinity (beta+gamma), and high-affinity (alpha+beta+gamma). The high-affinity trimeric receptor is found on activated T cells and regulatory T cells, enabling responses to picomolar concentrations of IL-2. In contrast, natural killer cells express the intermediate-affinity receptor and require higher IL-2 levels for activation.
Regulation by proteolytic shedding
In simple terms: The alpha subunit of the IL-2 receptor can be cut off the cell surface, releasing a soluble form that can soak up IL-2 and modulate signaling.
The metalloprotease ADAM10 cleaves IL-2R alpha (CD25) at the cell surface, generating soluble CD25 (sCD25). This shedding reduces the availability of high-affinity receptors and can act as a decoy to limit IL-2 signaling. Elevated sCD25 levels are observed in inflammatory and autoimmune conditions, and sCD25 is used as a biomarker.
Therapeutic targeting of IL-2R binding
In simple terms: Drugs and engineered proteins can block or enhance IL-2 binding to its receptor for treating diseases.
Monoclonal antibodies such as basiliximab and daclizumab bind to CD25 and block IL-2R binding, preventing T-cell activation in transplant rejection. Conversely, engineered IL-2 mimics (e.g., 'superkines') with selective binding to beta/gamma or alpha/beta/gamma receptors are being developed to preferentially expand effector T cells or regulatory T cells for cancer immunotherapy and autoimmune disease. Small molecules like triptolide can also inhibit IL-2/IL-2R signaling.
Key Genes Involved in GO:0005134 interleukin-2 receptor binding
The following genes encode the ligands, receptor subunits, and signaling molecules directly involved in interleukin-2 receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL2 | Encodes interleukin-2, the primary ligand that binds IL-2R. | Knockout mice develop severe autoimmunity; used to study T-cell homeostasis. |
| IL2RA | Encodes CD25, the alpha subunit of IL-2R; confers high-affinity binding. | Target for immunosuppressive antibodies; mutations cause immunodeficiency. |
| IL2RB | Encodes CD122, the beta subunit; shared with IL-15R. | Essential for intermediate-affinity binding and signaling. |
| IL2RG | Encodes CD132, the common gamma chain; shared by multiple cytokine receptors. | Mutations cause X-linked severe combined immunodeficiency (SCID). |
| JAK1 | Janus kinase 1; phosphorylates STATs downstream of IL-2R. | Target for JAK inhibitors in autoimmune diseases. |
| JAK3 | Janus kinase 3; associates with CD132 and is critical for IL-2 signaling. | Mutations cause SCID; target for immunosuppression. |
| STAT5A | Signal transducer and activator of transcription 5A; mediates IL-2-induced gene expression. | Key effector of IL-2R signaling; knockout impairs T-cell proliferation. |
| STAT5B | STAT5B; similar to STAT5A, involved in IL-2 signaling. | Mutations affect immune regulation and growth. |
| PIK3CA | Phosphatidylinositol 3-kinase catalytic subunit alpha; activated by IL-2R. | Plays role in IL-2-induced survival signals. |
| PIK3R1 | PI3K regulatory subunit 1; modulates PI3K activity downstream of IL-2R. | Mutations linked to immunodeficiency and autoimmunity. |
| HRAS | Ras proto-oncogene; mediates MAPK pathway activation by IL-2R. | Involved in T-cell proliferation and oncogenesis. |
| ADAM10 | Metalloprotease that cleaves CD25 to generate soluble CD25. | Regulates IL-2 bioavailability; target for modulating immune responses. |
| IL15 | Interleukin-15; shares receptor subunits with IL-2 and can bind IL-2R beta/gamma. | Used to study differential signaling and design mimics. |
| FOXP3 | Forkhead box P3; master regulator of regulatory T cells that depend on IL-2R signaling. | Mutations cause IPEX syndrome; relevant to tolerance. |
| CD4 | CD4 molecule; marker of helper T cells that express IL-2R upon activation. | Used to identify IL-2-responsive T cell subsets. |
| CD8A | CD8 alpha chain; marker of cytotoxic T cells that respond to IL-2. | Target for engineering CAR-T cells with IL-2 signaling. |
| NKG2D | Natural killer group 2 member D; not directly binding IL-2 but marks NK cells that respond to IL-2. | Used to study IL-2 effects on NK cells. |
| BCL2 | B-cell lymphoma 2; anti-apoptotic protein induced by IL-2R signaling. | Mediates survival signals downstream of IL-2. |
How Is interleukin-2 receptor binding Regulated?
Interleukin-2 receptor binding and signaling are tightly regulated at multiple levels. Receptor expression is controlled by transcription factors such as NF-κB and NFAT following T-cell activation. The affinity of the receptor is modulated by the availability of subunits; CD25 is rapidly upregulated upon activation, converting cells to high-affinity responders. Proteolytic shedding of CD25 by ADAM10 reduces surface receptor density and generates soluble CD25 that can sequester IL-2. Intracellularly, signaling is attenuated by phosphatases (e.g., SHP-1) and SOCS proteins that feedback on JAK/STAT pathways. Additionally, IL-2R signaling is influenced by the metabolic state of the cell, with mTOR integrating nutrient and growth factor signals. These regulatory mechanisms ensure appropriate immune responses and prevent autoimmunity.
interleukin-2 receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL2RA | CD25 deficiency, autoimmunity, transplant rejection | Knockout mice, human T-cell lines with CRISPR KO |
| IL2RB | Immunodeficiency, autoimmunity | Knock-in mice with point mutations |
| IL2RG | X-linked SCID | Patient-derived iPSCs with CRISPR correction |
| JAK3 | SCID, autoimmune diseases | Conditional knockout mice, cell lines |
| ADAM10 | Inflammation, cancer, Alzheimer's disease | Overexpression and knockout models |
Autoimmune diseases and transplant rejection
Dysregulated IL-2R binding contributes to autoimmunity by promoting excessive T-cell activation. For example, in rheumatoid arthritis, elevated soluble CD25 correlates with disease activity, and blocking IL-2R with antibodies (e.g., basiliximab) is used to prevent transplant rejection. Triptolide, an immunosuppressive compound, inhibits IL-2/IL-2R signaling and reduces inflammation in models of autoimmune disease.
Cancer and immunotherapy
IL-2R binding is exploited in cancer immunotherapy to boost anti-tumor T-cell responses. High-dose IL-2 is approved for metastatic melanoma and renal cell carcinoma, but severe toxicity limits its use. Engineered IL-2 mimics with selective binding to the intermediate-affinity receptor (beta/gamma) preferentially expand effector T cells over regulatory T cells, improving the therapeutic index. Conversely, blocking IL-2R with antibodies can deplete regulatory T cells and enhance anti-tumor immunity.
Immunodeficiency
Mutations in genes encoding IL-2R subunits (IL2RG, IL2RA, IL2RB) or downstream signaling molecules (JAK3, STAT5) cause severe immunodeficiency. X-linked SCID results from IL2RG mutations, leading to absent T and NK cells. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX)-like syndrome with autoimmunity and immunodeficiency.
Inflammatory and infectious diseases
Soluble CD25 is elevated in many inflammatory conditions, including sepsis, COVID-19, and hemophagocytic lymphohistiocytosis, reflecting immune activation. ADAM10-mediated shedding of CD25 is a regulatory mechanism that can be targeted to modulate inflammation. In infections, IL-2R binding supports the expansion of pathogen-specific T cells, but excessive signaling can contribute to immunopathology.
From interleukin-2 receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IL2RA abolish high-affinity IL-2 binding? | IL2RA knockout in Jurkat or primary T cells via CRISPR |
| How does a point mutation in IL2RB affect JAK/STAT signaling? | Knock-in of specific mutations in cell lines |
| Can a tagged IL2RA be used to track receptor internalization? | Knock-in of fluorescent tag (e.g., GFP) at IL2RA locus |
| What is the effect of IL2 overexpression on T-cell proliferation? | Lentiviral overexpression in primary T cells |
| Which genes regulate IL-2R surface expression? | Genome-wide CRISPR knockout library screening |
| How does ADAM10-mediated shedding affect IL-2 signaling? | ADAM10 knockout or overexpression in cell lines |
How to Study the interleukin-2 receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding kinetics and affinity (Kd) | Characterizing IL-2/IL-2R interactions |
| Flow cytometry | Cell surface receptor expression and ligand binding | Analyzing CD25+ T cell subsets |
| Phospho-flow | Phosphorylation of STAT5 as signaling readout | Assessing IL-2R activation in single cells |
| ELISA | Soluble CD25 or cytokine levels | Biomarker detection in serum |
| CRISPR knockout screening | Genes required for IL-2R binding or signaling | Identifying novel regulators |
| Cryo-EM/X-ray crystallography | 3D structure of ligand-receptor complex | Structure-guided design of mimics |
| Biolayer interferometry (BLI) | Real-time binding kinetics | Comparing wild-type and mutant IL-2 |
| Reporter assays | Transcriptional activation downstream of IL-2R | Screening for pathway modulators |
Binding assays (SPR, BLI, ELISA)
Surface plasmon resonance (SPR) and biolayer interferometry (BLI) measure real-time binding kinetics (kon, koff, Kd) between IL-2 and its receptor subunits. ELISA-based assays can quantify soluble CD25 or competitive binding of antibodies. These methods are used to characterize engineered IL-2 mimics and blocking antibodies.
Flow cytometry and phospho-flow
Flow cytometry with fluorescently labeled IL-2 or anti-CD25 antibodies assesses receptor expression and binding on the cell surface. Phospho-flow detects phosphorylated STAT5 as a readout of IL-2R signaling activation at the single-cell level. These techniques are essential for studying immune cell subsets and responses to IL-2.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that regulate IL-2R binding, surface expression, or downstream signaling. For example, a screen for regulators of IL-2-induced proliferation may reveal novel components of the pathway. CRISPR activation (CRISPRa) and interference (CRISPRi) libraries allow gain- and loss-of-function studies.
Structural biology and modeling
X-ray crystallography and cryo-electron microscopy have solved structures of IL-2 bound to its receptor subunits, revealing the molecular details of the binding interface. Computational modeling and molecular dynamics simulations predict the effects of mutations on binding affinity. These methods guide the design of IL-2 mimics with altered receptor selectivity.
How CRISPR Can Be Used to Study GO:0005134 interleukin-2 receptor binding
Knockout
CRISPR knockout of IL2RA, IL2RB, or IL2RG in T-cell lines or primary T cells abolishes IL-2R binding and downstream signaling, providing a clean background to study receptor function. Knockout of ADAM10 prevents CD25 shedding, increasing surface receptor levels. These models are used to validate drug targets and understand immune regulation.
Point Mutation
Introducing point mutations in the IL-2 binding interface or receptor subunits via CRISPR base editing or homology-directed repair allows precise dissection of binding affinity and signaling. For example, mutations in IL2RB that impair JAK3 binding can be modeled to study immunodeficiency. Point mutations in IL2RA can mimic disease-associated variants.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags (e.g., HA) at the endogenous IL2RA locus enables real-time tracking of receptor expression, internalization, and trafficking. Knock-in of patient-specific mutations into cell lines or mice recapitulates disease phenotypes for drug testing. Knock-in of inducible promoters allows controlled expression of IL-2 or its receptor.
Overexpression
Overexpression of IL2, IL2RA, or constitutively active JAK3 in cell lines or primary T cells using lentiviral vectors enhances IL-2R binding and signaling, useful for studying gain-of-function effects. Overexpression of soluble CD25 can act as a decoy to inhibit IL-2 signaling. These models help identify oncogenic or autoimmune drivers.
How EDITGENE Supports interleukin-2 receptor binding Research
Researchers studying interleukin-2 receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor expression, ligand binding, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes implicated in GO:0005134.
Contact EDITGENE today to design your custom CRISPR model for interleukin-2 receptor binding research.
Frequently Asked Questions About interleukin-2 receptor binding
What is interleukin-2 receptor binding?
Interleukin-2 receptor binding (GO:0005134) is the molecular function of a ligand, such as IL-2, physically interacting with the interleukin-2 receptor complex on the cell surface, initiating signaling.
What genes are involved in interleukin-2 receptor binding?
Key genes include IL2 (ligand), IL2RA (CD25), IL2RB (CD122), IL2RG (CD132), and downstream signaling molecules like JAK1, JAK3, and STAT5A/B.
What is the function of GO:0005134?
GO:0005134 describes the binding activity that mediates cytokine-receptor interaction, leading to activation of JAK/STAT, PI3K, and MAPK pathways that control T-cell proliferation and survival.
How is interleukin-2 receptor binding studied?
It is studied using binding assays (SPR, BLI), flow cytometry, phospho-flow, CRISPR screens, and structural biology techniques like cryo-EM.
What diseases are associated with interleukin-2 receptor binding?
Dysregulation is linked to autoimmune diseases, transplant rejection, cancer, and immunodeficiencies such as X-linked SCID.
What is the role of CD25 in IL-2 receptor binding?
CD25 (IL-2R alpha) is the subunit that confers high-affinity binding to IL-2, allowing responses to low cytokine concentrations.
How does ADAM10 regulate IL-2 receptor binding?
ADAM10 cleaves CD25 from the cell surface, generating soluble CD25 that can sequester IL-2 and modulate signaling.
Can CRISPR be used to study interleukin-2 receptor binding?
Yes, CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect the function of IL-2R subunits and signaling components.
What are IL-2 mimics and how do they relate to receptor binding?
IL-2 mimics are engineered proteins designed to bind IL-2R subunits with altered selectivity, aiming to enhance anti-tumor immunity or reduce toxicity.
What is the clinical significance of soluble CD25?
Soluble CD25 is a biomarker of immune activation and is elevated in autoimmune diseases, infections, and transplant rejection.
Conclusion
Interleukin-2 receptor binding (GO:0005134) is a fundamental molecular function that governs immune cell activation and homeostasis. Its precise regulation is critical for mounting effective immune responses while preventing autoimmunity. Advances in structural biology, protein engineering, and CRISPR-based genomics have deepened our understanding of this binding event and opened new therapeutic avenues. Continued research into the IL-2/IL-2R axis promises to yield safer and more effective immunotherapies for cancer, autoimmune diseases, and immunodeficiency.
References
- 1. Xiong Y et al.. 2024. Immunosuppressive effects of triptolide via interleukin-2/receptor signaling.. Immunopharmacol Immunotoxicol 46(6):727-740 PMID: 39290043
- 2. Marino P et al.. 1991. [The interleukin-2 receptor].. Recenti Prog Med 82(5):291-3 PMID: 1887156
- 3. Kirschke S et al.. 2022. The metalloprotease ADAM10 generates soluble interleukin-2 receptor alpha (sCD25) in vivo.. J Biol Chem 298(6):101910 PMID: 35398356
- 4. Silva DA et al.. 2019. De novo design of potent and selective mimics of IL-2 and IL-15.. Nature 565(7738):186-191 PMID: 30626941
- 5. Cantrell DA et al.. 1993. Regulation of PtdIns-3-kinase and the guanine nucleotide binding proteins p21ras during signal transduction by the T cell antigen receptor and the interleukin-2 receptor.. Semin Immunol 5(5):319-26 PMID: 8260648
- 6. Takakura K. 1997. [Interleukin-2 receptor].. Nihon Rinsho 55 Suppl 2:520-5 PMID: 9172581
- 7. Liparoto SF et al.. 1999. Biosensor analysis of the interleukin-2 receptor complex.. J Mol Recognit 12(5):316-21 PMID: 10556880
- 8. Morris JC et al.. 2000. Advances in interleukin 2 receptor targeted treatment.. Ann Rheum Dis 59 Suppl 1(Suppl 1):i109-14 PMID: 11053100
